The EPS beat and cash runway extension are positive, but the stock's trajectory depends entirely on PLN-101095 clinical data. Interim FORTIFY data expected in 2027, no near-term catalysts. Monitor for any partnership or financing announcements given the $76M market cap and $172.4M cash position.
PLRX drugs
PLRX drug pipeline →Price Chart
Executive Summary
Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than the $56.2M loss in Q1 2025, driven by lower R&D and G&A expenses after terminating the BEACON-IPF trial. The company dosed the first patient in the FORTIFY Phase 1b trial of PLN-101095 and presented encouraging updated Phase 1 data at AACR. Cash runway extends into H2 2028, but the stock remains a binary event-driven name with no approved products or revenue.
Key Financial Metrics
Key Facts
- Net loss of $20.0M in Q1 2026 vs $56.2M in Q1 2025, a 64% improvement
- EPS of -$0.32 vs consensus estimate of -$0.36, a 11.1% beat
- Cash, cash equivalents and short-term investments of $172.4M as of March 31, 2026, sufficient into H2 2028
- First patient dosed in FORTIFY Phase 1b trial of PLN-101095 in April 2026
- Updated Phase 1 data at AACR showed deepening confirmed responses in ICI-refractory tumors
- No revenue reported, pre-revenue clinical-stage biotech
- R&D expenses fell to $13.6M from $43.4M YoY due to BEACON-IPF close-out and headcount reduction
Financial Impact
Net loss improved by $36.2M YoY to $20.0M; EPS beat consensus by $0.04
Risk Factors
- No approved products or revenue, entirely dependent on clinical trial success
- PLN-101095 is in early-stage trials (Phase 1b) with interim data not expected until 2027
- Cash burn rate: $20M/quarter implies ~2.2 years of runway, but no revenue to offset
- Historical insider selling pattern (prior cluster filings) may indicate management caution
- Only 9% analyst bullish rating, Street is skeptical
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001746473-26-000088 |
| Document: plrx-20260511.htm | 0001746473-26-000088 |
| Document: 0001746473-26-000088-index-headers.html | 0001746473-26-000088 |
| Document: 0001746473-26-000088-index.html | 0001746473-26-000088 |
| Document: 0001746473-26-000088.txt | 0001746473-26-000088 |
| 8-K Data (Synthetic) | 0001746473-26-000088 |
Track record
8 reports on PLRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 Viewing No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers